Literature DB >> 19251165

Radiofrequency ablation for the treatment of stage I non-small cell lung neoplasm.

Arjun Pennathur1, Ghulam Abbas, Rodney J Landreneau, James D Luketich.   

Abstract

Lung cancer is the most common cause of cancer related mortality in the United States. Surgical resection is the standard treatment for stage I non-small cell lung cancer (NSCLC). However, many patients who have resectable cancer may have significant comorbidities precluding surgical resection. Radiofrequency ablation is an emerging modality of treatment and may be applicable in this high-risk group of patients. In this article, we review the principles of radiofrequency ablation, the common devices in use, and the results of treatment for stage I non-small cell lung neoplasm.

Entities:  

Mesh:

Year:  2008        PMID: 19251165     DOI: 10.1053/j.semtcvs.2008.11.003

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  4 in total

Review 1.  Emerging treatment options in the management of non-small cell lung cancer.

Authors:  Pier Luigi Filosso; Alberto Sandri; Alberto Oliaro; Andrea Riccardo Filippi; Maria Carla Cassinis; Umberto Ricardi; Paolo Olivo Lausi; Sofia Asioli; Enrico Ruffini
Journal:  Lung Cancer (Auckl)       Date:  2011-06-08

Review 2.  Image-guided radiofrequency ablation for the treatment of early-stage non-small cell lung neoplasm in high-risk patients.

Authors:  Arjun Pennathur; Ghulam Abbas; Matthew J Schuchert; Rodney J Landreneau; James D Luketich
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

3.  Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases.

Authors:  Xia Yang; Xin Ye; Aimin Zheng; Guanghui Huang; Xiang Ni; Jiao Wang; Xiaoying Han; Wenhong Li; Zhigang Wei
Journal:  J Surg Oncol       Date:  2014-06-25       Impact factor: 3.454

4.  Percutaneous local tumor ablation vs. stereotactic body radiotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Dongjie Chen; Man Zhao; Xiaoyong Xiang; Jun Liang
Journal:  Chin Med J (Engl)       Date:  2022-07-14       Impact factor: 6.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.